Background
Phase III, double-blind, placebo-controlled RCT. 4805 patients with HER2+ early breast cancer (node-positive or node-negative with additional risk factors) who had undergone surgery. Adjuvant pertuzumab + trastuzumab vs trastuzumab alone for 1 year, alongside standard adjuvant chemotherapy. Largest adjuvant HER2+ trial to date.
Interventions and follow up
Arm A: Pertuzumab 420mg q3wk (loading 840mg) + trastuzumab 6mg/kg q3wk (loading 8mg/kg) × 18 cycles + adjuvant chemotherapy (anthracycline-taxane or taxane-carboplatin)
Arm B: Placebo + trastuzumab × 18 cycles + chemotherapy
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 74.1 months (6-yr analysis)
Arm B: Placebo + trastuzumab × 18 cycles + chemotherapy
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 74.1 months (6-yr analysis)
Results
IDFS (6-yr): 90.6% vs 87.8%, HR 0.76, 95% CI 0.64–0.91, P=.0001
IDFS (node-positive, 6-yr): 88.7% vs 84.9%, HR 0.72
OS (8-yr): HR 0.85, 95% CI 0.70–1.04 — not significant
IDFS (node-positive, 6-yr): 88.7% vs 84.9%, HR 0.72
OS (8-yr): HR 0.85, 95% CI 0.70–1.04 — not significant
Adverse events
GI: grade ≥3 diarrhea 9.8% vs 3.7%
Cardiac: symptomatic cardiac events 0.7% vs 0.3%; LVEF decline ≥10% 4.1% vs 3.2%
Other: pertuzumab adds diarrhea but minimal cardiac or hematologic toxicity beyond trastuzumab alone
Cardiac: symptomatic cardiac events 0.7% vs 0.3%; LVEF decline ≥10% 4.1% vs 3.2%
Other: pertuzumab adds diarrhea but minimal cardiac or hematologic toxicity beyond trastuzumab alone
Conclusions
Dual HER2 blockade (pertuzumab + trastuzumab) significantly improved IDFS vs trastuzumab alone in adjuvant HER2+ early BC, primarily benefiting node-positive patients. OS was numerically improved but not statistically significant at 8-year analysis.
Key Limitations
Key Limitations: Absolute IDFS benefit is modest (~2.8% at 6 years in all-comers; ~3.8% in node-positive). OS non-significant — the small absolute IDFS benefit raises questions about cost-effectiveness in lower-risk patients. Node-negative subgroup showed minimal benefit; guidelines restrict use to node-positive or high-risk node-negative patients. Pertuzumab adds significant cost and diarrhea burden. The KATHERINE trial subsequently changed management of residual-disease patients, redirecting the prognostic risk group where pertuzumab may provide less relative benefit.
Clinical Context
Pertuzumab + trastuzumab adjuvant therapy (Perjeta/Herceptin) received FDA approval in 2017 for node-positive HER2+ early BC. ESMO-MCBS score: 3. Guidelines (ASCO, ESMO) recommend dual HER2 blockade + chemotherapy for high-risk (particularly node-positive) adjuvant patients. For patients with residual disease post-NACT, KATHERINE (T-DM1) supersedes pertuzumab continuation, and DESTINY-Breast05 (T-DXd) is the emerging new standard.
References